Purpose: Eosinophilic Esophagitis (EE) is an increasingly recognized condition in adults characterized by esophageal mucosal eosinophilia in the setting of dysphagia or food impaction. We undertook a retrospective review of all cases seen in our Gastroenterology Clinic to evaluate for demographic information including gender predeliction, presenting symptoms including dysphagia score, associated conditions, endoscopic and histologic appearance and response to treatment. Methods: A retrospective review of medical records from January 2003 to August 2006 was completed. Data was analyzed by calculating means with standard deviations for continuous variables and percentages for categorical variables. Dysphagia scores were assessed based on presenting history and reassessed based on further progress notes when available. Statistical calculations were completed with the aid of SAS software. Results: Twenty-five patients were identified. Age at presentation was 26.1 ± 6.4 years. Age at symptom onset was 23.8 ± 7.8 years. 94% of patients were male. 96% of patients presented with solid dysphagia or food bolus impaction. 92% of patients had either concentric rings or linear furrows reported on initial endoscopy. Biopsy revealed 47 ± 40 eos/hpf (range 26–200). 22% of patients also were asthmatic and 55% of patients had a history of asthma, atopy and/or a positive allergy skin test. Patients were treated with a variety of modalities including dilation, PPI's, food avoidance and swallowed fluticasone. Patients had significantly less dysphagia after treatment (median score 2.4 prior to treatment and 0.7 after treatment, P < 0.01) and there was no trend favoring a specific treatment. There were no perforations or significant complications from dilation. Conclusion: EE is a recently recognized disease of increasing frequency. Early recognition and treatment of EE could prevent food impaction and the risk of mucosal tears with treatment. One should suspect EE in younger men with solid dysphagia and any history of allergic disease. EE appears responsive to a variety of therapies. Dilation appeared safe in our series in contrast to prior series that showed substantial perforation rates. Potential areas for further study include prospective trials of specific treatment modalities and symptom recurrence after intervention.